Clinical Trials
Currently Recruiting
-
Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Fallopian Tube Tumours, Malignant Pleural Mesothelioma, Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma of the Oral Cavity, Triple Negative Breast Cancer
Sponsor: In-house
Principal Investigator: Drs. Lillian Siu & Anna Spreafico (Second PI)
NCT#: NCT03686202
-
Prospective Analysis of INteStinal Microbiome and Autoimmune PanEls as PrediCtors of Toxicity in Phase I ImmunOncology Patients (INSPECT-IO)Eligible Tumour Type(s): Solid Cancer
Sponsor: In-house
Principal Investigator: Dr. Anna Spreafico
NCT#: NCT04107311
-
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (LANDMARC)Eligible Tumour Type(s): Epstein-Barr virus- and human papillomavirus -related cancers, Hepatocellular carcinoma
Sponsor: In-house
Principal Investigator: Dr. Kathy Han
NCT#: NCT04665388
-
ADP-0000-001
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
Principal Investigator: Dr. Marcus Butler
NCT#: NCT02636855
-
ADP-0055-001
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Principal Investigator: Dr. Marcus Butler
NCT#: NCT04044859
-
ADP-0044-002
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Principal Investigator: Dr. Albiruni Razak
NCT#: NCT04044768
-
IOV-COM-202
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT03645928
-
IMCnyeso-101
A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer
Principal Investigator: Dr. Marcus Butler
NCT#: NCT03515551
-
GSK208467
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Principal Investigator: Dr. Albiruni Razak
NCT#: NCT03967223
-
GSK208750
Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT03391778